Bio-Rad Laboratories, Inc. Class A BIO
NYSE · United States · Health Technology
$377.71-1.84 (-0.48%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Biologics, biosimilars and personalized therapies are fueling CDMO outsourcing, while AI, automation and single-use systems enable scalable, compliant protein production.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Manufacturing Services Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Recombinant Proteins Manufacturing Services Market to Reach US$15.3 Billion by 2030 The global recombinant proteins manufacturing services m
Bio-Rad Laboratories (BIO) has drawn attention after recent share performance data showed a decline of about 2% over the past month, alongside a gain of roughly 27% over the past three months. At a share price of US$377.71, Bio-Rad Laboratories has seen short term share price momentum cool over the past month. However, the 90 day share price return of about 27% and 1 year total shareholder return of roughly 27% suggest sentiment has improved compared with the much weaker 5 year total...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.